Cashu
Syndax Pharmaceuticals Advances Oncology Pipeline Amid Market Challenges and Competition
3 months ago
Stocks
Health Care
sndx
Syndax Pharmaceuticals
NASDAQ: SNDX
-0.64 (-3.03%)
20.5
USD
At close at Feb 13, 21:41 UTC
Overview
Loading chart...
Key Stats
Market Cap
1.76B
Dividend Yield
0.00%
P/E Ratio
-5.66
EPS
-3.72
Revenue
23.68M
Avg. Volume
1.25M
About
What does SNDX do?
Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.